MannKind Corp Reports Q1 2026 Total Revenues of $90.2 Million

MannKind Corporation (NASDAQ:MNKD) reported total revenues of $90.2 million for the first quarter of 2026, a 15% increase compared to Q1 2025. The growth was driven by Furoscix net sales and increased royalties from United Therapeutics, despite a decline in collaboration revenue.

By Maham Fatima Mon, May 18, 2026 at 7:50 AM GMT+3 2 min read · Yahoo Finance · May 18, 2026, 04:50 UTC

MannKind Corp Reports Q1 2026 Total Revenues of $90.2 Million

Tickers: $MNKD $UTHR

Topics: biopharmaceuticals FDA action dates revenue

Read the full article at Yahoo Finance

More World news

Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC
Bit Digital Reports Q3 2026 Net Income of $28.5 Million Amid Revenue Decline Motley Fool · November 12, 2026, 18:26 UTC
EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC
Sabre Corp Shares Decline Following Travelport Denial of Merger Speculation Seeking Alpha · November 12, 2026, 18:21 UTC
Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC
Beachbody (BODi) Reduces Annual Revenue Breakeven to $125 Million Amid Strategic Pivot Motley Fool · November 12, 2026, 18:15 UTC
Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC